BOSTON, MA--(MARKET WIRE)--Jan 30, 2007 -- Solos Endoscopy, Inc. (Other OTC:SLSY.PK - News) is pleased to announce that the Company has completed its capital restructuring and will be operating under the new symbol SLSY. The Solos Endoscopy Board of Directors approved the capital restructure as a means to position the Company to be more attractive for possible investment candidates, to reduce the market volatility that Solos Endoscopy shares have experienced, and to better reflect the Company’s earnings as compared to other companies in the medical equipment market.
Solos Endoscopy, Inc. recently announced that the Company has launched worldwide its new Solos Breast Endoscopy System. Solos Endoscopy will roll out the system to hospitals and doctors throughout the world. The Solos Breast Endoscopy System is ideal for performing Mammary Ductoscopy procedures, which allows physicians to examine the mammary ducts under direct visualization.
Clinical studies have shown that Breast Endoscopy (Mammary Ductoscopy) is capable of visualizing lesions consistent with ADH and early stages of cancer at dramatically smaller sizes than is currently possible through mammography. With the Solos System, physicians worldwide can find breast cancer and precancerous breast lesions as small as 0.2mm in diameter. This is 25 times smaller than is typically seen on a standard mammogram. This means the tumor can be found up to 5 years earlier -- while still confined within the mammary ducts where treatment survival rates of 99% have been reported. The Company will be posting information on the new system on their website at www.solosendoscopy.com.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos’ sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company’s website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
To automatically receive instant updates, press releases, and other information on this and other Big Apple Consulting USA companies, please visit http://www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple ComPro.
Contact: Contact: Investor Relations for Solos Endoscopy, Inc. 1-866-THE-APPL(E)
Source: Solos Endoscopy, Inc.
